Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Recommendation of “Hold” from Brokerages

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) have earned an average rating of “Hold” from the six analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $8.00.

MIST has been the subject of a number of recent research reports. Wells Fargo & Company boosted their price target on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Wall Street Zen upgraded shares of Milestone Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 29th. TD Cowen raised shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 15th. Finally, Zacks Research cut shares of Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 24th.

Insiders Place Their Bets

In related news, CEO Joseph Oliveto sold 43,000 shares of Milestone Pharmaceuticals stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $2.25, for a total transaction of $96,750.00. Following the transaction, the chief executive officer directly owned 303,721 shares in the company, valued at approximately $683,372.25. The trade was a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 113,693 shares of company stock worth $233,347 in the last quarter. 19.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in MIST. Sapient Capital LLC purchased a new position in shares of Milestone Pharmaceuticals during the 3rd quarter valued at about $25,000. Strategic Family Wealth Counselors L.L.C. bought a new position in shares of Milestone Pharmaceuticals during the 4th quarter valued at approximately $25,000. Eaton Financial Holdings Company LLC purchased a new stake in Milestone Pharmaceuticals in the 4th quarter worth approximately $26,000. Bank of America Corp DE raised its stake in Milestone Pharmaceuticals by 200,550.0% during the 3rd quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after acquiring an additional 16,044 shares during the period. Finally, Stephenson & Company Inc. bought a new stake in Milestone Pharmaceuticals during the 3rd quarter worth approximately $40,000. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Price Performance

NASDAQ MIST opened at $1.04 on Monday. The stock has a market capitalization of $122.38 million, a price-to-earnings ratio of -1.32 and a beta of 0.48. Milestone Pharmaceuticals has a 1-year low of $0.63 and a 1-year high of $3.06. The company has a debt-to-equity ratio of 1.37, a current ratio of 8.01 and a quick ratio of 7.96. The business’s fifty day moving average price is $1.72 and its 200-day moving average price is $1.97.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings data on Friday, March 20th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. The firm had revenue of $1.44 million for the quarter, compared to analysts’ expectations of $37.52 million. On average, equities analysts predict that Milestone Pharmaceuticals will post -0.62 earnings per share for the current year.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.